Elucidating the Genomic and Proteomic Parameters for Restenotic Patients

碩士 === 中國醫藥大學 === 生物科技學系 === 96 === Percutaneous transluminal coronary angioplasty is often applicated for clinical treatment of stenosis after atherosclerosis;however, there are about 30-50% patients who will have restenosis within 6 months. Even using the stents, there are also 10-30% patients who...

Full description

Bibliographic Details
Main Authors: Hsiang-Tien Huang, 黃湘恬
Other Authors: 吳介信
Format: Others
Language:zh-TW
Published: 2008
Online Access:http://ndltd.ncl.edu.tw/handle/06194148742021701062
Description
Summary:碩士 === 中國醫藥大學 === 生物科技學系 === 96 === Percutaneous transluminal coronary angioplasty is often applicated for clinical treatment of stenosis after atherosclerosis;however, there are about 30-50% patients who will have restenosis within 6 months. Even using the stents, there are also 10-30% patients who will have restenosis. Although Drug-eluting stents can reduce the incidence of restenosis to less than 10%, government health insurance only provides partial financial support, bringing an economic burden on these patients. Therefore, restenosis is a limiting factor after percutaneous transluminal coronary angioplasty. Proteome is an important research area which can link genome to this devastating disease. The deduced proteins can be the bio-markers responsible for this disease. Since blood is easy to get to make a diagnosis, this study therefore aims to explore the serum parameters from patients who have restenosis or not after percutaneous transluminal coronary angioplasty. In the previous study, We find that the expression of α2- macroglobulin and haptoglobin (2-1 phenotype) are related to restenosis. Single nucleotide polymorphysims of restenotic and non-restenotic human genome were also studied.